Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004864 · ClinicalTrials.gov registry record · Phase 1
Docetaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors
A Phase 1 study, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00004864 is a Phase 1 study that has completed, run by Montefiore Medical Center.
The verdict
NCT00004864, a Phase 1 study, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Gene therapy such as GEM 231 may inhibit the growth of cancer cells and make the tumor more sensitive to chemotherapy. PURPOSE: Phase I trial to study the effectiveness of combining docetaxel and GEM 231 in treating patients who have recurrent or refractory solid tumors.
Interventions
- DRUG docetaxel
- DRUG GEM 231
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-07 |
| Est. Completion | 2000-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004864
The ClinicalTrials.gov registry entry for NCT00004864 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which docetaxel is the first listed.
NCT00004864 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004864 about?
NCT00004864 is a clinical study titled "Docetaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Gene therapy such as GEM 231 may inhibit the growth of cancer cells and make the tumor more sensitive to chemotherapy. PURPOSE: Phase I trial to study the effectiveness of combini...
What is the current status of trial NCT00004864?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-07. Estimated completion is 2000-06.
What interventions are being tested in trial NCT00004864?
The interventions under investigation include: docetaxel (DRUG), GEM 231 (DRUG).
Who is sponsoring clinical trial NCT00004864?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.